🇺🇸 FDA
Patent

US 10076520

Use of tyrosine kinase inhibitor in cancer treatment

granted A61KA61K31/496A61K31/5025

Quick answer

US patent 10076520 (Use of tyrosine kinase inhibitor in cancer treatment) held by The Regents of the University of Colorado, a Body Corporate expires Mon Sep 13 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of Colorado, a Body Corporate
Grant date
Tue Sep 18 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 13 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
9
CPC classes
A61K, A61K31/496, A61K31/5025, A61K31/506, A61K31/517